A report released today by Zacks Investment Research about Acacia Research Corp (NASDAQ:ACTG) raises the target price to $6.75
- Updated: October 11, 2016
Acacia Research Corp (NASDAQ:ACTG) had its target price raised to $6.75 by Zacks Investment Research in an issued report issued 10/11/2016. The updated stock price target indicates a possible upside of 0.13% based on the company's last stock close price.
Only yesterday Acacia Research Corp (NASDAQ:ACTG) traded -2.94% lower at $5.95. ACTG’s 50-day average is $6.34 and its two hundred day average is $5.19. The last close is up 14.54% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 410,741 shares of the stock were exchanged, down from an average trading volume of 512,592
See Chart Below
Acacia Research Corp has a one year low of $2.82 and a one year high of $9.77 Acacia Research Corp’s market capitalization is currently $0.
Brief Synopsis On Acacia Research Corp (NASDAQ:ACTG)
Acacia Research Corporation, through its subsidiaries, is engaged in patent investment, prosecution, licensing and enforcement activities. The Company's subsidiaries partner with inventors and patent owners for patented inventions. The Company operates in patent licensing and enforcement business segment. The Company's subsidiaries generate revenues from the granting of intellectual property rights for the use of patented technologies that its subsidiaries control or own. The Company's subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. It is engaged in licensing and enforcing patented technologies. Its subsidiaries include Adaptix, Inc. and Body Science, LLC.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.